50 Participants Needed

Ritlecitinib for Scarring Alopecia

GS
Overseen ByGiselle Singer
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known as cicatricial alopecia (CA), in which hair follicles are irreversibly destroyed. CA leads to scarred areas, most commonly on the scalp, that cannot re-grow hair. Despite being a long-term condition, that often has significant impact on patients' well-being, available effective treatments for these diseases are lacking. In addition, the molecular abnormalities causing CA are largely unknown. The research team will be administering a new investigational drug (a JAK3/TEC inhibitor), ritlecitinib, which has shown statistically significant improvement in scalp hair loss for AA patients in a proof of concept and phase 2b/3 studies (B7981015 AA study). This is an open-label clinical trial. CA patients will be asked to provide small samples of skin and blood throughout the treatment period, to find out how they respond to the drug, and to attempt to better understand these diseases.

Research Team

Emma Guttman - Dermatology | Mount ...

Emma Guttman-Yassky

Principal Investigator

Icahn School of Medicine at Mount Sinai

Eligibility Criteria

Adults over 18 with scarring alopecia for at least 6 months, in good health, and not pregnant or breastfeeding can join. They must test negative for TB, agree to use effective contraception if applicable, and have no acute infections or planned surgeries. Excluded are those with certain systemic diseases causing hair loss, psychiatric conditions affecting study compliance, a history of severe allergies to drug components or recent use of immunosuppressive medications.

Inclusion Criteria

Subjects who are willing and able to adhere to the study visit schedule and comply with protocol requirements
I have had central centrifugal cicatricial alopecia for at least 6 months.
I am not pregnant or breastfeeding, and if able to have children, I use effective birth control and have negative pregnancy tests.
See 2 more

Exclusion Criteria

I haven't taken part in any drug trials within the last 4 weeks or 5 half-lives of the drug.
I have had alopecia for over 7 years, have severe scarring, or am losing hair very quickly.
I do not have active hepatitis B, C, or HIV.
See 17 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Ritlecitinib, starting with 200 mg once-daily for 8 weeks, followed by 100 mg once daily for the remaining 40 weeks

48 weeks
Regular visits for skin and blood sample collection

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Ritlecitinib
Trial Overview The trial is testing Ritlecitinib (PF-06651600), a new drug for cicatricial alopecia—a condition where scarred areas on the scalp cannot regrow hair. This open-label trial will involve participants providing skin and blood samples to assess their response to the treatment and understand the disease better.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: PF-06651600 (Ritlecitinib)Experimental Treatment1 Intervention
200 mg once-daily for 8 weeks and then 100 mg once daily for the remaining 40 weeks

Ritlecitinib is already approved in European Union, United States for the following indications:

🇪🇺
Approved in European Union as Litfulo for:
  • Severe alopecia areata
🇺🇸
Approved in United States as Litfulo for:
  • Severe alopecia areata

Find a Clinic Near You

Who Is Running the Clinical Trial?

Emma Guttman

Lead Sponsor

Trials
4
Recruited
190+

Pfizer

Industry Sponsor

Trials
4,712
Recruited
50,980,000+
Known For
Vaccine Innovations
Top Products
Viagra, Zoloft, Lipitor, Prevnar 13

Albert Bourla

Pfizer

Chief Executive Officer since 2019

PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki

Patrizia Cavazzoni profile image

Patrizia Cavazzoni

Pfizer

Chief Medical Officer

MD from McGill University

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security